Kexing Biopharm Co., Ltd. (SHA:688136)
China flag China · Delayed Price · Currency is CNY
16.00
+0.47 (3.03%)
Nov 5, 2026, 3:00 PM CST

Kexing Biopharm Cash Flow Statement

Millions CNY. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
70.36155.5731.48-190.29-90.396.46
Depreciation & Amortization
106.06107.04100.8288.2671.0449.88
Other Amortization
9.018.035.911.019.976.75
Loss (Gain) From Sale of Assets
-0.95-0.95-0.08-0.28-1.460.47
Asset Writedown & Restructuring Costs
0.610.610.171.60.422.94
Loss (Gain) From Sale of Investments
-110.06-110.0619.65-7.171.52-56.65
Provision & Write-off of Bad Debts
0.810.811.4-3.130.17-1.77
Other Operating Activities
141.1942.2842.8135.5722.9710.99
Change in Accounts Receivable
-224.91-224.91-228.07-70.17-85.91-66.53
Change in Inventory
0.250.2545.89-14.87-35.26-59.28
Change in Accounts Payable
92.9192.9169.46124.9360.42111.97
Change in Other Net Operating Assets
5.185.184.377.727.85-
Operating Cash Flow
99.7486.03106.67-87.14-85.8994.01
Operating Cash Flow Growth
116.15%-19.35%----11.25%

Investing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Capital Expenditures
-101.17-83.63-93.99-191.2-399.17-371.98
Sale of Property, Plant & Equipment
0.191.170.04-1.7864.47
Cash Acquisitions
--1.07----
Divestitures
-13.5----
Investment in Securities
95.02-7.95-8.3712.05--200
Other Investing Activities
12.7614.22-1.822.915.9415.01
Investing Cash Flow
6.8-63.76-104.13-156.25-381.45-492.5

Financing Activities

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Long-Term Debt Issued
-916.43627.66420.631,016505.52
Long-Term Debt Repaid
--742.84-569.77-371.69-591.08-284.65
Lease Payments
-10.42-10.42-10.31-17.68--
Net Debt Issued (Repaid)
80.7173.5957.8848.93424.72220.88
Issuance of Common Stock
-19.256.967.82--
Repurchase of Common Stock
-40.75-49.25-31.13---
Common Dividends Paid
-92-57.38-43.63-45.41-53.63-28.39
Other Financing Activities
26.15-12.9-14.91--5.55
Financing Cash Flow
-25.9173.31-10.9116.25371.1186.94

Net Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Foreign Exchange Rate Adjustments
-7.34-0.211.393.095.43-2.07
Net Cash Flow
73.2995.37-6.98-224.04-90.81-213.61

Free Cash Flow

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-1.432.412.68-278.34-485.06-277.97
Free Cash Flow Growth
--81.05%----
Free Cash Flow Margin
-0.11%0.16%0.90%-22.11%-36.86%-21.63%
Free Cash Flow Per Share
-0.010.010.06-1.40-2.42-1.41
Levered Free Cash Flow
61.72-96.15-98.13-244.19-461.11-246.11
Unlevered Free Cash Flow
68.63-69.5-70.1-218.74-443.17-241.1
Free Cash Flow After Leases
-11.85-8.022.37-296.01-485.06-277.97

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash Income Tax Paid
78.0857.7660.5149.5435.3541.63
Change in Working Capital
-117.3-117.3-95.48-22.7-100.22-15.07